Heron Therapeutics (HRTX) Tops Q3 EPS by 12c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.17), $0.12 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $31.43 million versus the consensus estimate of $32.75 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Barclays upgrades CubeSmart, cuts Public Storage on relative valuation
• Delta Air shares slip despite strong outlook, Melius says